Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00458289
Recruitment Status : Completed
First Posted : April 10, 2007
Last Update Posted : March 12, 2009
Information provided by:
University of Illinois at Chicago

Brief Summary:

Patients with end-stage renal disease (ESRD) commonly have high concentrations of phosphorous, a mineral, in the blood (hyperphosphatemia). This is a result of their inability to excrete phosphorous by the kidneys. This in turn may result in the development of a condition known as secondary hyperparathyroidism and renal osteodystrophy or bone disease. As such, these patients often receive medications known as phosphate binders such as calcium carbonate or acetate, sevelamer, aluminum hydroxide and lanthanum carbonate to manage and treat hyperphosphatemia.

Lanthanum carbonate is a newly available phosphate binding agent that is effective in the management of hyperphosphatemia and preventing secondary hyperparathyroidism. It works in the gastrointestinal tract by binding to the phosphorus in the diet. ESRD patients taking lanthanum carbonate are counseled to chew the tablets completely before swallowing, with or immediately after meals. However, patients who are intubated or receiving nutrition via feeding tubes are unable to chew the tablets. For these patients, medications are commonly crushed and administered via the tube. Moreover, some patients prefer to crush the tablets and mix it with food instead of chewing. To date, it is not known if crushing the lanthanum carbonate tablets prior to administration and taking it with food would be as effective as chewing them.

The purpose of this study is to compare the efficacy of phosphate binding between chewed and crushed lanthanum carbonate tablets.

Condition or disease Intervention/treatment Phase
Hyperphosphatemia in Chronic Kidney Disease Drug: Lanthanum carbonate (chewed vs. crushed) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
No Intervention: 1
P-containing meal alone
Active Comparator: 2
P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
Drug: Lanthanum carbonate (chewed vs. crushed)
single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
Active Comparator: 3
P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
Drug: Lanthanum carbonate (chewed vs. crushed)
single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder

Primary Outcome Measures :
  1. Serum phosphorous concentration [ Time Frame: Hourly from time=0-8 h after administration of meal and drug ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men and women at least 18 years of age
  • No clinically significant abnormal findings on clinical laboratory evaluation and medical history
  • Within 15% of ideal body weight for height and build according to the Metropolitan Life tables5
  • Women of child-bearing potential (premenopausal and not surgically sterilized) who have a negative pregnancy test
  • Women who are sexually active must be using effective means of contraception

Exclusion Criteria:

  • History of dysphagia or swallowing disorders
  • Clinically significant illness within 3 months of study enrollment
  • Concomitant use of medication that might interact with lanthanum carbonate
  • Pregnant or intends to become pregnant within 30 days of completing the study
  • Breast feeding
  • Alcohol or controlled substance abuse
  • Use of an investigational agent within 30 days of study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00458289

United States, Illinois
University of Illinois at Chicago, Dept of Pharmacy Practice
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
University of Illinois at Chicago
Principal Investigator: Alan H Lau, Pharm.D. University of Illinois at Chicago Identifier: NCT00458289     History of Changes
Other Study ID Numbers: 2006-0530
First Posted: April 10, 2007    Key Record Dates
Last Update Posted: March 12, 2009
Last Verified: March 2009

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Phosphorus Metabolism Disorders
Metabolic Diseases